According to the World Health Organization’s estimations, there are currently 264 million people suffering from depression and/or anxiety, costing the global economy $1 Trillion. In response, Canadian company MYND Life Sciences has partnered with private vaccine developer Eyam to develop a suite of central nervous system disorder treatment protocols.
According to a corporate update from Dr. Lyle Oberg, CEO of MYND, in early July, the goals of the licensing agreement include the development of assessment tools including diagnostic biomarkers, psilocybin and other psychedelic therapies, and vaccines and immunotherapies.
“This agreement with Eyam will allow MYND to access yet another cutting edge technology with the development of vaccines that have the ability to prevent neurological disorders such as major depressive disorder, by stopping the neuro-inflammatory process before it starts,” explains Dr. Oberg.
MYND Life Science Inc. is a life sciences company at the forefront of the development of alternative mental health therapies. Dr. Wilfred Jefferies, Chief Science Officer, has secured access to Health Canada psilocybin research and development and has filed patents based on therapeutic approaches to treating central nervous system diseases utilizing psychedelics and other neuroactive agents.
“We recognize that traditional pharmaceuticals have not been effective in treating many forms of Major Depressive Disorder (MDD.) We believe that psilocybin has the ability to change the course of depression by working on pathways that we have already identified in prior research,” stated Dr. Jefferies. “This Agreement allows my team to expand our research development and delve deeper into the fundamental cause of depression leading to new treatments and diagnostics.”
MYND has plans to develop methods for the treatment of Alzheimer’s disease and related forms of dementia.
